Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 9/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 11/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13554345 | 0.86 | GSK3B (0.60) | GSK3BDYRK1ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL15942816 | 0.85 | HDAC3 (0.51) | GSK3BDYRK1ASMN1; SMN2KDM4EWNT1 | |
| SCHEMBL13554357 | 0.82 | YTHDC1 (0.60) | GSK3BRAB9ANPC1LMNA | |
| SCHEMBL13386776 | 0.81 | DYRK1A (0.47) | GSK3BDYRK1ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13267443 | 0.78 | KDM4E (0.61) | GSK3BSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL2056320 | 0.77 | HAO1 (0.57) | GSK3BSMN1; SMN2RAB9ANPC1LMNA | |
| SCHEMBL13554360 | 0.76 | JAK2 (0.50) | GSK3BDYRK1ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL12583332 | 0.75 | GSK3B (0.49) | GSK3BDYRK1ASMN1; SMN2KDM4EGAA | |
| SCHEMBL21311366 | 0.74 | DYRK1A (0.72) | GSK3BDYRK1AWNT1 | |
| SCHEMBL8373049 | 0.72 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802688-B2 | Substituted acetyl-coa carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | GSK3B 326/4885DYRK1A 4172/4885SMN1; SMN2 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.